NCT05600452

Comparison of a Novel Condensed Heat Acclimation Programme With a Traditional Longer-term Heat Acclimation Programme

Completed NA Last updated 6 December 2023

What this trial tests

NA trial testing Heat acclimation in Heat Stress in 37 participants. Completed in 4 January 2023.

Timeline

17 January 2020

Primary endpoint
4 January 2023

4 January 2023

Quick facts

Lead sponsor	University of Portsmouth
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	37
Start date	17 January 2020
Primary completion	4 January 2023
Estimated completion	4 January 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

• Heat acclimation

Conditions studied

• Heat Stress — all drugs for Heat Stress →

Sponsor

University of Portsmouth

Who can join

Adults 18 to 45, male only, with Heat Stress. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Repeated exposure to heat in a laboratory setting (acclimation) elicits a range of adaptations, which reduce heat illness risk and increase work capacity in the heat. Traditional approaches to heat acclimation require daily heat exposures of 1 to 2 hours over \~7 to 10 consecutive days. Heat acclimation approaches which reduce the number of days to achieve acclimation may have utility. The primary purpose of the proposed research is to determine whether it is possible to achieve a similar degree of heat acclimation to that seen with a traditional longer-term heat acclimation approach by increasing the frequency of heat exposure, utilising multiple daily heat exposures over a smaller number of days. Secondary aims of the research are to examine whether heat acclimation provides cross-adaptation to a hypoxic stressor and whether heat acclimation improves aerobic fitness.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Lipocalin 2-not only a biomarker: a study of current literature and systematic findings of ongoing clinical trials.
   Asaf S, Maqsood F, Jalil J, Sarfraz Z, et al · · 2023 · cited 38× · PMID 36529828 · DOI 10.1007/s12026-022-09352-2